

# 해외 바이오의약품 임상 현황 ('24년 1월 3주)

한국바이오의약품협회, 2024.01.23.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.  
- 출처: ClinicalTrials.gov  
- 모니터링 기간: 2024.01.15.~2024.01.21.  
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 18건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06138639</a>	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)	Genetic: SGT-003	Solid Biosciences Inc.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06138639</a>
<a href="#">NCT05932199</a>	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	Drug: Durvalumab / tremelimumab Drug: Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab	Baylor College of Medicine Duke Cancer Institute	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT05932199</a>
<a href="#">NCT06209619</a>	CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Golcadomide Procedure: Positron Emission Tomography Biological: Rituximab	Nathan Denlinger Bristol-Myers Squibb Ohio State University Comprehensive Cancer Center	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06209619</a>
<a href="#">NCT06202066</a>	Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Incomplete Freund's Adjuvant Procedure: Magnetic Resonance Imaging Biological: Sargramostim Biological: SVN53-67/M57-KLH Peptide Vaccine Drug: Temozolomide	Roswell Park Cancer Institute	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06202066</a>
<a href="#">NCT06137183</a>	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)	Drug: Vixarelimab Drug: Placebo	Genentech, Inc.	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06137183</a>
<a href="#">NCT06120075</a>	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Drug: AB801 Drug: Zimberelimab Drug: Docetaxel	Arcus Biosciences, Inc.	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06120075</a>
<a href="#">NCT06107738</a>	Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma	Drug: Iberdomide Drug: Daratumumab/rHuPH20 Co-formulation	Barbara Ann Karmanos Cancer Institute Bristol-Myers Squibb Janssen Pharmaceuticals Multiple Myeloma Research Consortium	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT06107738</a>
<a href="#">NCT06100744</a>	A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	Drug: Adalimumab Drug: Risankizumab	AbbVie	Phase 3	<a href="#">https://clinicaltrials.gov/study/NCT06100744</a>
<a href="#">NCT06062966</a>	The Effects of IL-1 Blockade on Inotropic Sensitivity in Patients With Heart Failure (AID-HEART)	Drug: Anakinra	Virginia Commonwealth University	Phase 1	<a href="#">https://clinicaltrials.gov/study/NCT06062966</a>
<a href="#">NCT05967182</a>	A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma	Drug: Pembrolizumab Drug: Gemcitabine Drug: Cisplatin	M.D. Anderson Cancer Center	Phase 2	<a href="#">https://clinicaltrials.gov/study/NCT05967182</a>

# 해외 바이오의약품 임상 현황 ('24년 1월 3주)

한국바이오의약품협회, 2024.01.23.

## ○ 미국 18건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05993611</a>	Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation	Procedure: Biopsy Procedure: Biospecimen Collection Biological: Chimeric Antigen Receptor T-Cell Therapy Procedure: Computed Tomography Procedure: Echocardiography Other: Electronic Health Record Review Procedure: Leukapheresis Procedure: Lumbar Puncture Procedure: Magnetic Resonance Imaging Other: Quality-of-Life Assessment Biological: Tafasitamab Procedure: X-Ray Imaging	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	<a href="https://clinicaltrials.gov/study/NCT05993611">https://clinicaltrials.gov/study/NCT05993611</a>
<a href="#">NCT05923073</a>	A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Drug: Guselkumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	<a href="https://clinicaltrials.gov/study/NCT05923073">https://clinicaltrials.gov/study/NCT05923073</a>
<a href="#">NCT05887882</a>	Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors	Biological: Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells Procedure: Implantation	Sabine Mueller, MD, PhD Rally Foundation Washington University School of Medicine Nationwide Children's Hospital University of California, San Francisco	Phase 1	<a href="https://clinicaltrials.gov/study/NCT05887882">https://clinicaltrials.gov/study/NCT05887882</a>
<a href="#">NCT05617833</a>	Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage	Combination Product: MLT+EPO Other: Placebo	Johns Hopkins University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	<a href="https://clinicaltrials.gov/study/NCT05617833">https://clinicaltrials.gov/study/NCT05617833</a>
<a href="#">NCT06205290</a>	A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies	Biological: Liso-cell Drug: Idelalisib Drug: Rituximab Drug: Bendamustine Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 3	<a href="https://clinicaltrials.gov/study/NCT06205290">https://clinicaltrials.gov/study/NCT06205290</a>
<a href="#">NCT06153251</a>	A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma	Drug: BMS-986453 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	<a href="https://clinicaltrials.gov/study/NCT06153251">https://clinicaltrials.gov/study/NCT06153251</a>
<a href="#">NCT06133010</a>	A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients	Biological: mRNA-1647 Biological: Placebo	ModernaTX, Inc.	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06133010">https://clinicaltrials.gov/study/NCT06133010</a>
<a href="#">NCT06046274</a>	GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	Biological: Pembrolizumab Biological: Acasunlimab	Genmab BioNTech SE	Phase 2	<a href="https://clinicaltrials.gov/study/NCT06046274">https://clinicaltrials.gov/study/NCT06046274</a>

## ○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06205290</a>	A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies	Biological: Liso-cell Drug: Idelalisib Drug: Rituximab Drug: Bendamustine Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 3	<a href="https://clinicaltrials.gov/study/NCT06205290">https://clinicaltrials.gov/study/NCT06205290</a>

# 해외 바이오의약품 임상 현황 ('24년 1월 3주)

한국바이오의약품협회, 2024.01.23.

## ○ 프랑스 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06175390</a>	Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer	Radiation: 68Ga-FAPI-46 PET/CT Biological: Tumor samples analysis Biological: Blood samples analysis: Circulating Tumor DNA	Institut Curie Hoffmann-La Roche	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06175390">https://clinicaltrials.gov/ct2/show/study/NCT06175390</a>
<a href="#">NCT05300035</a>	Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control	Drug: Recombinant human monoclonal antibody (bNAbs) Drug: Placebo	ANRS, Emerging Infectious Diseases Rockefeller University Institut Pasteur	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05300035">https://clinicaltrials.gov/ct2/show/study/NCT05300035</a>
<a href="#">NCT06205290</a>	A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies	Biological: Liso-cel Drug: Idelalisib Drug: Rituximab Drug: Bendamustine Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06205290">https://clinicaltrials.gov/ct2/show/study/NCT06205290</a>
<a href="#">NCT06153251</a>	A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma	Drug: BMS-986453 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06153251">https://clinicaltrials.gov/ct2/show/study/NCT06153251</a>

## ○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06205290</a>	A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies	Biological: Liso-cel Drug: Idelalisib Drug: Rituximab Drug: Bendamustine Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Celgene Corporation	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06205290">https://clinicaltrials.gov/ct2/show/study/NCT06205290</a>
<a href="#">NCT06153251</a>	A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma	Drug: BMS-986453 Drug: Fludarabine Drug: Cyclophosphamide	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06153251">https://clinicaltrials.gov/ct2/show/study/NCT06153251</a>

## ○ 중국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT03807102</a>	Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer	Biological: Tumor Vaccine	Yongchang Zhang Shanghai Houchao Biotechnology Co., Ltd Hunan Province Tumor Hospital	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03807102">https://clinicaltrials.gov/ct2/show/study/NCT03807102</a>
<a href="#">NCT06211790</a>	Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma	Drug: Anlotinib, Everolimus and Tislelizumab	Fudan University	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06211790">https://clinicaltrials.gov/ct2/show/study/NCT06211790</a>
<a href="#">NCT06154707</a>	Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes	Drug: Denosumab Injection Other: Normal saline injection (1.0ml/ branch)	Wuhan Union Hospital, China	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06154707">https://clinicaltrials.gov/ct2/show/study/NCT06154707</a>
<a href="#">NCT06102824</a>	Organoid-based Functional Precision Therapy for Advanced Breast Cancer	Drug: Organoid-guided treatment Drug: Taxane Drug: Capecitabine Drug: Gemcitabine Drug: Vinorelbine Drug: Eribulin Drug: Anthracycline Drug: Carboplatin Drug: Utidelone Drug: Trastuzumab deruxtecan Drug: Sacituzumab govitecan	Guangdong Provincial People's Hospital First Affiliated Hospital, Sun Yat-Sen University Sun Yat-sen University Shantou Central Hospital	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06102824">https://clinicaltrials.gov/ct2/show/study/NCT06102824</a>
<a href="#">NCT05266846</a>	Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK	Drug: Pembrolizumab Combined With Bevacizumab and Chemotherapy	Hunan Province Tumor Hospital	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05266846">https://clinicaltrials.gov/ct2/show/study/NCT05266846</a>